Anti-Human/Mouse Integrin β7 (Clone FIB504) – Alexa Fluor® 647

TK1 Cells

This Alexa Fluor® 647 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Alexa Fluor® is a trademark of Life Technologies Corporation.

Liquid

This Alexa Fluor® 647 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Red Laser (633 nm) Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.

B,
WB,
IP

Clone FIB504 recognizes an epitope on human/mouse integrin β7.

Integrin β7 antibody, clone FIB504, recognizes integrin β7, a 130 kDa membrane glycoprotein of the Ig superfamily. Integrin β7 forms heterodimers with both the α4 (CD49d) and aE (CD103) integrins. α4β7 integrin is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors^1,2. It mediates adhesion to mucosal endothelial cells, promoting leukocyte transendothelial migration through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1)^3,4. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells^5,6, subsets of dendritic cells⁷, and regulatory T cells (Tregs)8. It facilitates retention in the gut epithelial layer via interactions with E-cadherin⁹. Anti-β7 antibodies block both the homing to and retention in the gut of pathogenic T cells¹⁰ and are currently under evaluation in a phase 3 clinical trial to treat inflammatory bowel disease¹¹.

Integrin α4β7 is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells, subsets of dendritic cells, and regulatory T cells (Tregs)⁸.

CD49d/β7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/β7: E-cadherin

1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905
2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26
3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8
4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93
5. Hadley GA Higgins JM. (2014) Adv Exp Med Biol. 819:97–110
6. Farstad IN., et al. (1996) Immunology. 89:227–37
7. Jaensson E., et al. (2008) J Exp Med. 205:2139–49
8. Allez M, et al. (2002) Gastroenterology. 123(5):1516-26
9. Schön MP, et al. (1999) J Immunol. 162(11):6641-9
10. Stefanich EG, et al. (2011) Br J Pharmacol. 162(8):1855-1870
11. Smids C, et al. (2017) J Crohns Colitis. 11(4):500-508